产品
编 号：F359146
分子式：C11H23NO4
分子量：233.3
分子式：C11H23NO4
分子量：233.3
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 441061-33-2
产品详情
生物活性：
Sinbaglustat (OGT2378) is a dual inhibitor of glucosylceramide synthase (GCS) and non-lysosomal glucosyl ceramidase (GBA2). Sinbaglustat is an orally available N-alkyl iminosugar that crosses the blood-brain barrier. Sinbaglustat can be used for the research of central neurodegenerative diseases associated with lysosomal dysfunctions.
体内研究：
Sinbaglustat (OGT2378; administered p.o., in the powdered chow, at a dose of 2500 mg/kg/day, corresponding to 35-40 mg of Sinbaglustat per mouse per day) is highly effective in impeding melanoma tumor growth?in vivo. The effectiveness of p.o. Sinbaglustat in this murine model suggests that inhibition of glycosphingolipid synthesis is a promising approach to inhibit tumor progression.Animal Model:Female syngeneic C57BL/6 mice, 6-8 weeks old bearing MEB4 melanoma tumor
Dosage:35-40 mg per mouse per day
Administration:Administered p.o., in the powdered chow, at a dose of 2500 mg/kg/day
Result:Inhibited MEB4 melanoma tumor growth in a syngeneic, orthotopic murine model.
体外研究：
Sinbaglustat (OGT2378; 20 μM) reduces the synthesis of glucosylceramide and ganglioside by 93% and >95% in MEB4 melanoma cells compared with untreated MEB4 cells, respectively, without either cytotoxic or antiproliferative effects.GBA2 is an enzyme involved in the catabolism of glycosphingolipids (GSLs).?Sinbaglustat is 50-fold more potent in inhibiting GBA2 than GCS.
Sinbaglustat (OGT2378) is a dual inhibitor of glucosylceramide synthase (GCS) and non-lysosomal glucosyl ceramidase (GBA2). Sinbaglustat is an orally available N-alkyl iminosugar that crosses the blood-brain barrier. Sinbaglustat can be used for the research of central neurodegenerative diseases associated with lysosomal dysfunctions.
体内研究：
Sinbaglustat (OGT2378; administered p.o., in the powdered chow, at a dose of 2500 mg/kg/day, corresponding to 35-40 mg of Sinbaglustat per mouse per day) is highly effective in impeding melanoma tumor growth?in vivo. The effectiveness of p.o. Sinbaglustat in this murine model suggests that inhibition of glycosphingolipid synthesis is a promising approach to inhibit tumor progression.Animal Model:Female syngeneic C57BL/6 mice, 6-8 weeks old bearing MEB4 melanoma tumor
Dosage:35-40 mg per mouse per day
Administration:Administered p.o., in the powdered chow, at a dose of 2500 mg/kg/day
Result:Inhibited MEB4 melanoma tumor growth in a syngeneic, orthotopic murine model.
体外研究：
Sinbaglustat (OGT2378; 20 μM) reduces the synthesis of glucosylceramide and ganglioside by 93% and >95% in MEB4 melanoma cells compared with untreated MEB4 cells, respectively, without either cytotoxic or antiproliferative effects.GBA2 is an enzyme involved in the catabolism of glycosphingolipids (GSLs).?Sinbaglustat is 50-fold more potent in inhibiting GBA2 than GCS.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备